Company Announcements

Futura Remuneration, Options & Total Voting Rights

Source: RNS
RNS Number : 5589M
Futura Medical PLC
12 January 2023
 

 12 January 2023

 

Futura Medical plc

("Futura" or the "Company")

Remuneration of Non-Executive Directors, Grant of Options and Total Voting Rights

 

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces the issue of 87,430 new ordinary shares of 0.2 pence each ("Ordinary Shares") in respect of the 2022 remuneration of its Non-Executive Directors and a grant of 4,444,942 options over Ordinary Shares ("Options") to employees and Directors.

 

Remuneration of Non-Executive Directors

 

In accordance with the terms of their service agreements, the Non-Executive Directors receive 25-30 per cent of their remuneration in the form of Ordinary Shares. For 2022, these were issued at 36.36 pence per share, being the average closing mid-market price of the last 10 trading days of 2021 (as announced via RNS on 13 January 2022).

 

The 87,430 new Ordinary Shares shall rank pari passu with the existing issued Ordinary Shares of the Company and have been issued as follows:

 

Director

Number of Ordinary Shares issued for 2022 remuneration

Total number of ordinary shares held

Percentage of the Company's resulting issued share capital

John Clarke

44,560

795,100

0.28%

Jeff Needham

16,344

16,344

0.01%

Andrew Unitt

26,526

26,526

0.01%

 

The shares element of the Non-Executive Directors' remuneration for 2023 will be awarded at 51.50 pence per Ordinary Share, being the average closing mid-market price of the last 10 trading days of 2022. The Non-Executive Directors will receive these shares in January 2024.

 

Grant of Options

 

The Company has granted a total of 4,444,942 Options of which 1,985,626 have been awarded to Directors as detailed below.

 

All Options have been granted under existing schemes and vest equally over 3 years to January 2025 with 25% of the Options granted with immediate vesting. The main condition is that the individual remains an employee or Director at the time of vesting.

 

Director

Number of Options granted

Exercise price

Total number of Options held following grant

James Barder

540,716

0.2p

2,085,716

Angela Hildreth

472,340

0.2p

1,508,340

John Clarke

463,343

0.2p

463,343

Ken James

509,227

0.2p

1,945,227

 

Total Voting Rights

 

Application has been made to the London Stock Exchange and it is anticipated that trading of the new Ordinary Shares will commence on AIM at 8:00am on 17 January 2023.

 

Immediately following the above issue, the Company will have 288,133,957 ordinary shares in issue, each carrying one voting right. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 288,133,957 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Further details are contained within the notifications below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full details of the Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.

ENDS

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.futuramedical.com

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction ("ED") through a unique evaporative mode of action. Futura has previously conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, using measures IIEF-EF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.

 

MED3000 is CE marked in Europe and CA marked in the UK as a clinically proven topical treatment for adult men with erectile dysfunction under the brand Eroxon™ with a key claim of "Helps you get an erection within 10 minutes".

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

John Clarke

2

Reason for the notification

a)

 

Position/status

 

Director/ PDMR

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Futura Medical plc

b)

 

LEI

 

21380053QLT46UNV2303

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 0.2p each

 

GB0033278473

b)

 

Nature of the transaction

 

Issue of shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

36.36 pence

44,560

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

11 January 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Jeff Needham

2

Reason for the notification

a)

 

Position/status

 

Director/ PDMR

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Futura Medical plc

b)

 

LEI

 

21380053QLT46UNV2303

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 0.2p each

 

GB0033278473

b)

 

Nature of the transaction

 

Issue of shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

36.36 pence

16,344

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

11 January 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Andrew Unitt

2

Reason for the notification

a)

 

Position/status

 

Director/ PDMR

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Futura Medical plc

b)

 

LEI

 

21380053QLT46UNV2303

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 0.2p each

 

GB0033278473

b)

 

Nature of the transaction

 

Issue of shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

36.36 pence

26,526

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

11 January 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

James Barder

2

Reason for the notification

a)

 

Position/status

 

Director/ PDMR

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Futura Medical plc

b)

 

LEI

 

21380053QLT46UNV2303

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Options over Ordinary shares of 0.2p each

 

GB0033278473

b)

 

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

nil

540,716

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

10 January 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Angela Hildreth

2

Reason for the notification

a)

 

Position/status

 

Director/ PDMR

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Futura Medical plc

b)

 

LEI

 

21380053QLT46UNV2303

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Options over Ordinary shares of 0.2p each

 

GB0033278473

b)

 

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

nil

472,340

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

10 January 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

John Clarke

2

Reason for the notification

a)

 

Position/status

 

Director/ PDMR

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Futura Medical plc

b)

 

LEI

 

21380053QLT46UNV2303

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Options over Ordinary shares of 0.2p each

 

GB0033278473

b)

 

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

nil

463,343

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

10 January 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Ken James

2

Reason for the notification

a)

 

Position/status

 

Director/ PDMR

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Futura Medical plc

b)

 

LEI

 

21380053QLT46UNV2303

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Options over Ordinary shares of 0.2p each

 

GB0033278473

b)

 

Nature of the transaction

 

Grant of Options over Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

nil

509,227

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

10 January 2023

f)

 

Place of the transaction

 

Outside of trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUCUGUPWGGP